- Country: Russia
- Summary: Supply of a Medicinal Product for Medical Use Dapagliflozin (For Citizens who have Suffered Acute Cerebrovascular Accident, Myocardial Infarction and other Acute...
- RUT Ref No: 128250967
- Deadline: 21 Oct 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: 191280.60
- Notice Type: Tender
- Document Ref. No.: 0816500000625014964
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Supply of the drug for medical use Dapagliflozin (for citizens who have suffered acute cerebrovascular accident, myocardial infarction and other acute cardiovascular diseases) for 2025
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINSupply of a Medicinal Product for Medical Use Dapagliflozin (For Citizens who have Suffered Acute Cerebrovascular Accident, Myocardial Infarction and other Acute... - Russian Tender
The STATE OF THE INSTITUAL OF THE REPUBLIC OF SAKHA (YAKUTIA) "CENTER OF THE REPUBLIC OF THE REPUBLIC OF SAKHA (YAKUTIA), a Government sector organization in Russia, has announced a new tender for Supply of a Medicinal Product for Medical Use Dapagliflozin (For Citizens who have Suffered Acute Cerebrovascular Accident, Myocardial Infarction and other Acute.... This tender is published on RussianTenders under RUT Ref No: 128250967 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-10-21.
The estimated tender value is 191280.60, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
